These studies demonstrated improved overall survival (OS) in patients with core-binding factor (CBF) AML (AML15) and improved OS with reduced 3-year cumulative incidence of relapse (AML16) [38,39]. This evidence concerns the gene CEBPZ and acute myeloid leukemia.